Pharmacologic Interventions

351 questions

All types351 Multiple choice182 Multiple select80 Ordering89

A 26-year-old pregnant woman, gravida 1 para 0, presents to her obstetrician at 16 weeks gestation for evaluation of a new rash. Over the past week, she has noted the appearance of non-pruritic, pink macules and papules spreading across her trunk and involving her palms and soles. She also reports mild fatigue and subjective low-grade fevers. Her first prenatal visit was two weeks ago, but she missed her scheduled laboratory testing. Her medical history is notable only for a severe anaphylactic reaction to amoxicillin during childhood, which resulted in wheezing and hospital admission. She takes a daily prenatal vitamin. Vital signs are within normal limits. Fetal heart tones are 145/min. Rapid plasma reagin testing is reactive at a titer of 1:32. A confirmatory Treponema pallidum particle agglutination test is also positive. Which of the following is the most appropriate next step in pharmacologic management?

Outpatient administration of oral doxycycline for 14 days

Intramuscular ceftriaxone administration for 14 days

Inpatient penicillin desensitization followed by intramuscular benzathine penicillin G

Oral azithromycin administration as a single dose

Observation with repeat non-treponemal serologic testing in 4 weeks

Show answer & explanation

Answer: Inpatient penicillin desensitization followed by intramuscular benzathine penicillin G

Answer

Inpatient penicillin desensitization followed by intramuscular benzathine penicillin G

The correct intervention is inpatient penicillin desensitization followed by intramuscular benzathine penicillin G. This patient is presenting with secondary syphilis (characterized by a rash involving the palms and soles, a positive RPR, and a positive TP-PA) during her pregnancy. Penicillin is the only antibiotic with proven, reliable efficacy for treating maternal infection and crossing the placenta to prevent congenital syphilis in the fetus. Because she has a history of a severe, IgE-mediated allergic reaction to penicillin (anaphylaxis to amoxicillin), she cannot be given alternative regimens safely or effectively; the strict standard of care dictates admission for desensitization followed by definitive treatment with benzathine penicillin G.

Step-by-Step Solution

Interpret the clinical and laboratory findings.

The patient has secondary syphilis, evidenced by the characteristic palmar and plantar rash, a positive RPR, and a positive TP-PA.

Accurate diagnosis is required before selecting targeted antimicrobial therapy.

Identify the patient's specific physiological state and medication constraints.

The patient is pregnant and has a severe, IgE-mediated (anaphylactic) allergy to penicillins.

Pregnancy restricts the use of teratogenic medications, and the severe allergy history complicates first-line drug selection.

Select the guideline-concordant pharmacologic intervention.

Determine that penicillin is mandatory for maternal-fetal syphilis treatment, necessitating a formal desensitization protocol.

Alternative agents lack established efficacy for preventing congenital syphilis or are strictly contraindicated in this population.

Key Concept

Pregnant patients with syphilis and a penicillin allergy must undergo penicillin desensitization and treatment with penicillin, as it is the only regimen proven to effectively treat the mother and prevent congenital syphilis.

Estimated Time:1m 15s

Question 2Question →

An emergency medical services team brings a 58-year-old man to the resuscitation bay due to progressive, profound weakness and an inability to stand. The patient's husband reports that the patient missed his last two hemodialysis appointments because of a local transportation strike. The patient has a known history of end-stage renal disease secondary to hypertensive nephrosclerosis, as well as type 2 diabetes mellitus. Upon arrival, he is lethargic but arousable. Vital signs include a blood pressure of 105/65 mmHg, a heart rate of 42/min, and a respiratory rate of 16/min. An immediate 12-lead electrocardiogram demonstrates marked sinus bradycardia with absent P waves, peaked T waves, and a widened QRS complex. A point-of-care basic metabolic panel reveals a serum potassium concentration of $7.8 \text{ mEq/L}$ . The clinical team consults nephrology for emergent hemodialysis but determines that temporizing pharmacologic stabilization is required immediately. Arrange the following pharmacologic interventions in the most appropriate sequential order for this patient's acute management.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence is: Intravenous calcium gluconate, followed by Intravenous regular insulin and 50% dextrose, followed by Oral sodium zirconium cyclosilicate.

The management of severe hyperkalemia with electrocardiographic changes requires a strict, prioritized approach: stabilize the myocardium, shift potassium intracellularly, and eliminate potassium from the body. Intravenous calcium gluconate is the absolute first priority as it rapidly antagonizes the membrane effects of hyperkalemia, preventing fatal arrhythmias within minutes. Once the myocardium is stabilized, intracellular shifting agents like intravenous regular insulin (co-administered with dextrose to prevent hypoglycemia) are used to temporarily lower serum potassium over 15 to 30 minutes. Finally, agents that physically remove potassium from the body, such as oral sodium zirconium cyclosilicate, are administered; these are given last in the acute sequence because they take hours to exert their effect while definitive therapy (hemodialysis) is arranged.

Step-by-Step Solution

Identify the life-threatening emergency.

The patient has severe hyperkalemia (

7.8 \text{ mEq/L}

) with active cardiac toxicity evidenced by bradycardia, absent P waves, peaked T waves, and a widened QRS complex.

Recognizing electrocardiographic changes in the setting of extreme hyperkalemia dictates an immediate, protocol-driven pharmacologic sequence prior to definitive dialysis.

Prioritize myocardial stabilization.

Intravenous calcium gluconate is administered as the absolute first step.

Without immediate membrane stabilization, the patient is at imminent risk of deteriorating into ventricular fibrillation or asystole. Calcium acts within minutes.

Initiate intracellular potassium shifting.

Intravenous regular insulin (with dextrose to prevent hypoglycemia) is administered next.

Once the myocardium is protected, shifting potassium into cells temporarily lowers the dangerous extracellular concentration. This bridge therapy takes 15 to 30 minutes to work.

Initiate total body potassium elimination.

Oral sodium zirconium cyclosilicate is administered last among these choices.

While definitive removal requires hemodialysis for this anuric patient, gastrointestinal binders contribute to potassium elimination but have a delayed onset of several hours.

Key Concept

Stepwise pharmacologic management of severe hyperkalemia with electrocardiographic changes: 1) Stabilize myocardium, 2) Shift potassium intracellularly, 3) Eliminate potassium.

Estimated Time:1m 30s

Question 3Question →

A 65-year-old man presents to a primary care clinic with a 4-day history of worsening cough productive of yellow sputum, subjective fevers, and fatigue. He has a past medical history of hypertension, type 2 diabetes mellitus, and hyperlipidemia. His daily medications include lisinopril, metformin, simvastatin, and low-dose aspirin. Vital signs show a temperature of 38.2°C (100.8°F), blood pressure of 134/82 mmHg, heart rate of 92/min, and respiratory rate of 18/min. Pulse oximetry is 96% on room air. Physical examination reveals crackles in the right lower lung base. A chest radiograph demonstrates a right lower lobe infiltrate. The physician diagnoses community-acquired pneumonia. Given the patient's comorbidities, he is prescribed an outpatient oral regimen of amoxicillin-clavulanate and clarithromycin. Which of the following is the most appropriate modification to this patient's chronic medication regimen during his antibiotic therapy?

Temporarily withhold simvastatin for the duration of the antibiotic course

Administer clarithromycin and simvastatin at least 12 hours apart

Continue all current medications and check serum creatine kinase in 3 days

Switch simvastatin to atorvastatin for the duration of therapy

Reduce the daily dosage of simvastatin by 50%

Show answer & explanation

Answer: Temporarily withhold simvastatin for the duration of the antibiotic course

Answer

Temporarily withhold simvastatin for the duration of the antibiotic course.

The correct action is to temporarily withhold simvastatin for the duration of the antibiotic course. Clarithromycin is a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme, which is responsible for the hepatic metabolism of simvastatin. Coadministration of these two drugs significantly elevates simvastatin serum concentrations, markedly increasing the risk of severe statin-induced myopathy and life-threatening rhabdomyolysis. Because of this well-established and predictable interaction, the concurrent use of simvastatin (or lovastatin) and clarithromycin is absolutely contraindicated by the FDA. The safest and most practical management strategy for a patient requiring a short course of a strong CYP3A4 inhibitor is to simply pause the statin therapy until the antibiotic course is completed, as a brief interruption in lipid-lowering therapy poses no acute cardiovascular risk.

Step-by-Step Solution

Analyze the prescribed antibiotic regimen for potential drug-drug interactions.

Clarithromycin is identified as a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme.

Macrolides (excluding azithromycin) are notorious for causing significant pharmacokinetic interactions by inhibiting hepatic enzymes.

Evaluate the patient's chronic medications to identify CYP3A4 substrates.

Simvastatin is identified as a major substrate of CYP3A4.

Inhibition of CYP3A4 drastically decreases the clearance of simvastatin, leading to toxic serum concentrations.

Determine the appropriate clinical intervention to mitigate the identified interaction.

The concurrent use of clarithromycin and simvastatin is absolutely contraindicated; the statin must be withheld.

To prevent severe adverse effects such as myopathy and rhabdomyolysis, the offending medication (simvastatin) should be paused during the short course of the antibiotic.

Key Concept

Management of pharmacokinetic interactions between strong CYP3A4 inhibitors (clarithromycin) and CYP3A4 substrates (simvastatin).

Estimated Time:1m 0s

Question 4Question →

A 72-year-old woman is evaluated in the ambulatory care clinic for a routine follow-up. She has a history of type 2 diabetes mellitus, osteoarthritis, hypertension, and recurrent uncomplicated urinary tract infections. Her current medications include metformin 1000 mg twice daily, sitagliptin 100 mg daily, meloxicam 15 mg daily, nitrofurantoin 100 mg daily, and amlodipine 10 mg daily. The patient reports feeling well overall, though she mentions mild fatigue over the past few weeks. Blood pressure is 132/82 mmHg, and pulse is 76/min. Physical examination is unremarkable, with no peripheral edema.

Laboratory results from today are compared to those from six months ago:

Laboratory Test	Current	Six Months Ago
Blood urea nitrogen	42 mg/dL	18 mg/dL
Serum creatinine	2.6 mg/dL	1.1 mg/dL
eGFR	19 mL/min/1.73 m²	55 mL/min/1.73 m²
Serum potassium	4.8 mEq/L	4.2 mEq/L

Based on the patient's current laboratory results, which of the following medications must be entirely DISCONTINUED? (Select all that apply)

Select all that apply

Metformin

Meloxicam

Nitrofurantoin

Sitagliptin

Amlodipine

Show answer & explanation

Answer: Metformin; Meloxicam; Nitrofurantoin

Answer

Metformin, Meloxicam, and Nitrofurantoin must be discontinued.

This patient has developed severe renal impairment (eGFR < 30 mL/min/1.73 m²). In this setting, metformin must be discontinued due to a significantly elevated risk of life-threatening lactic acidosis. Meloxicam, an NSAID, must be stopped because it inhibits prostaglandins that are actively dilating the afferent arteriole to maintain glomerular filtration, further worsening renal function. Nitrofurantoin must also be discontinued because it is essentially cleared by glomerular filtration; at an eGFR < 30 mL/min/1.73 m², it fails to reach therapeutic levels in the urinary tract to prevent UTIs and instead accumulates systemically, leading to pulmonary toxicity and peripheral neuropathy.

Step-by-Step Solution

Analyze the patient's updated laboratory findings.

The patient's eGFR has rapidly declined from 55 to 19 mL/min/1.73 m², indicating new-onset Stage 4 chronic kidney disease (CKD) or acute-on-chronic kidney injury.

Renal function directly determines the safety, efficacy, and necessary dosing adjustments for many pharmacologic agents.

Evaluate the current medication list against the new eGFR of 19 mL/min/1.73 m².

Identify which medications are absolutely contraindicated, which need dose adjustments, and which are safe to continue.

Continuing contraindicated medications in advanced CKD can lead to severe systemic toxicity or worsen renal failure.

Select the medications that require complete discontinuation.

Metformin (lactic acidosis risk), meloxicam (worsens renal perfusion), and nitrofurantoin (lack of efficacy and high toxicity risk) must be stopped. Sitagliptin only requires a dose reduction, and amlodipine requires no changes.

Differentiating between drugs requiring dose adjustments and those requiring absolute discontinuation is critical for safe medication reconciliation.

Key Concept

Medication reconciliation and identification of absolute pharmacologic contraindications in the setting of severely impaired renal function (eGFR < 30 mL/min/1.73 m²).

Question 5Question →

A 33-year-old woman comes to the clinic to discuss her medication regimen. She was recently diagnosed with estrogen receptor-positive breast cancer and underwent a lumpectomy with sentinel lymph node biopsy two weeks ago. Her oncologist plans to initiate adjuvant tamoxifen therapy next week. The patient has a 5-year history of major depressive disorder, which has been well controlled for the past two years with daily paroxetine. She reports that her mood is currently stable and she has no neurovegetative symptoms of depression, though she is mildly anxious about starting her new cancer treatment. She has no other medical conditions and takes no other medications. Vital signs are within normal limits. Physical examination reveals a healing surgical incision on the right breast, with no erythema or discharge. Which of the following is the most appropriate next step in the pharmacologic management of this patient's depression?

Continue paroxetine at the current dosage

Discontinue paroxetine and initiate fluoxetine

Discontinue paroxetine and initiate bupropion

Discontinue paroxetine and initiate venlafaxine

Continue paroxetine and increase the planned dosage of tamoxifen

Show answer & explanation

Answer: Discontinue paroxetine and initiate venlafaxine

Answer

Discontinue paroxetine and initiate venlafaxine

The correct course of action is to discontinue paroxetine and initiate venlafaxine. Tamoxifen is a selective estrogen receptor modulator (SERM) used as adjuvant therapy for hormone receptor-positive breast cancer. It is a prodrug that must be converted by the hepatic cytochrome P450 2D6 (CYP2D6) enzyme into its highly active metabolite, endoxifen. Paroxetine is a strong inhibitor of CYP2D6. Co-administration of paroxetine and tamoxifen prevents the formation of endoxifen, leading to reduced therapeutic efficacy and an increased rate of breast cancer recurrence. Venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), is a weak or non-inhibitor of CYP2D6. It is considered a safe and highly effective alternative for treating depression (as well as hot flashes) in patients taking tamoxifen.

Step-by-Step Solution

Identify the patient's concurrent medications and planned therapies.

The patient is currently taking paroxetine for major depressive disorder and is scheduled to begin tamoxifen for estrogen receptor-positive breast cancer.

Medication reconciliation is the critical first step to avoid adverse drug events when new therapies are introduced.

Evaluate potential pharmacokinetic and pharmacodynamic interactions.

Paroxetine is identified as a strong CYP2D6 inhibitor. Tamoxifen is a prodrug that requires activation by CYP2D6 into its active metabolite, endoxifen.

Concomitant use of a strong CYP2D6 inhibitor prevents the activation of tamoxifen, significantly reducing its efficacy and increasing the risk of breast cancer recurrence.

Determine the appropriate clinical intervention to manage the interaction.

Select an effective alternative antidepressant that does not strongly inhibit CYP2D6, such as venlafaxine.

Venlafaxine safely maintains psychiatric stability without compromising the efficacy of the patient's critical oncologic therapy.

Key Concept

Management of drug-drug interactions involving CYP2D6 inhibitors and tamoxifen

Alternative Method

While venlafaxine is an excellent choice, selective serotonin reuptake inhibitors (SSRIs) that are weak or non-inhibitors of CYP2D6, such as escitalopram or citalopram, are also safe and viable alternative options for managing depression in patients on tamoxifen.

Estimated Time:1m 0s

Question 6Question →

A 31-year-old man is brought to the emergency department by his partner due to severe confusion, high fever, and intractable vomiting for the past 12 hours. The partner reports that the patient was diagnosed with Graves disease two years ago but has been nonadherent to all medications for the past three months. Temperature is 40.1°C (104.2°F), pulse is 155/min, blood pressure is 162/68 mm Hg, and respirations are 26/min. Physical examination reveals a profusely diaphoretic and delirious patient. A prominent fine tremor is noted in the upper extremities. Neck examination reveals a diffusely enlarged, non-tender thyroid gland with an audible bruit. Electrocardiography demonstrates sinus tachycardia.

Arrange the following pharmacologic interventions in the strictly required chronological sequence for the acute management of this patient's condition.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence is intravenous propranolol, followed by oral propylthiouracil, followed by potassium iodide solution.

The management of thyroid storm requires a strict sequence of pharmacologic interventions to prevent exacerbating the condition. Intravenous propranolol is given first to rapidly control severe sympathetic symptoms (e.g., tachycardia, hyperpyrexia, agitation) and reduce peripheral conversion of T4 to T3. Next, a thionamide such as propylthiouracil (PTU) is administered to halt the synthesis of new thyroid hormone. Finally, an iodine solution (such as potassium iodide) is given to block the release of preformed thyroid hormone (the Wolff-Chaikoff effect). The iodine must be given at least one hour after the thionamide to ensure synthesis is completely blocked; otherwise, the iodine will serve as a substrate and worsen the hyperthyroidism.

Step-by-Step Solution

Administer intravenous propranolol

Rapid reduction in sympathetic overdrive and inhibition of peripheral T4 to T3 conversion

Immediate stabilization of cardiovascular status and control of adrenergic symptoms is the highest priority in thyroid storm.

Administer oral propylthiouracil (PTU)

Inhibition of thyroid peroxidase and blocking of new hormone synthesis

Synthesis of new thyroid hormone must be halted before exposing the hyperactive gland to a heavy iodine load.

Administer potassium iodide solution

Inhibition of preformed thyroid hormone release

Iodine must be given approximately 1 hour after PTU to prevent the iodine from being utilized as a substrate to produce more thyroid hormone.

Key Concept

Chronological pharmacologic sequence in the management of thyroid storm

Alternative Method

In patients with severe asthma or heart failure where non-selective beta-blockers like propranolol are contraindicated, alternative sympatholytic agents such as esmolol (cardioselective, short-acting) or diltiazem (calcium channel blocker) may be used as the first step.

Estimated Time:1m 0s

Question 7Question →

A $74$ -year-old man is evaluated on the inpatient medical ward. He was admitted $3$ days ago for a severe exacerbation of chronic obstructive pulmonary disease. His home medications include warfarin for permanent atrial fibrillation and a tiotropium inhaler. On admission, he was started on intravenous methylprednisolone and oral levofloxacin. Today, he reports feeling much better with decreased dyspnea and minimal cough. His vital signs are stable, with a blood pressure of $128/76$ mm Hg and a heart rate of $78$ /min. Routine morning laboratory results show an International Normalized Ratio (INR) of $7.2$ (target $2.0$ - $3.0$ ). Physical examination reveals no petechiae, ecchymoses, or signs of gastrointestinal bleeding. Which of the following is the most appropriate next step in the management of this patient's pharmacotherapy?

Omit the next one to two doses of warfarin, monitor the coagulation profile, and resume at a lower dose.

Administer intravenous phytonadione and withhold the next dose of warfarin.

Administer four-factor prothrombin complex concentrate and withhold warfarin.

Withhold warfarin and administer phytonadione via the intramuscular route.

Discontinue levofloxacin, substitute with intravenous ceftriaxone, and continue the current warfarin dose.

Show answer & explanation

Answer: Omit the next one to two doses of warfarin, monitor the coagulation profile, and resume at a lower dose.

Answer

The most appropriate next step is to omit the next one to two doses of warfarin, monitor the coagulation profile, and resume at a lower dose.

The correct answer involves withholding the next one to two doses of warfarin and monitoring the patient's coagulation profile. Current clinical guidelines state that for patients taking warfarin who present with an asymptomatic supratherapeutic INR between

4.5

and

10

, the routine use of phytonadione (Vitamin K) is not recommended. The safest and most effective approach is to hold warfarin until the INR falls back into the therapeutic range (

2.0

3.0

), and then resume it at a lower dose if the interacting medications (in this case, levofloxacin and methylprednisolone) are continued.

Step-by-Step Solution

Analyze the patient's clinical presentation and laboratory results.

The patient has an asymptomatic supratherapeutic INR of 7.2 without any signs of active bleeding.

Determining the presence or absence of active bleeding is the critical branching point in managing warfarin-associated coagulopathy.

Identify the likely cause of the coagulopathy.

The recent addition of levofloxacin and methylprednisolone caused a pharmacokinetic interaction, inhibiting warfarin metabolism and altering gut flora.

Understanding the etiology helps guide future dose adjustments once the INR returns to the therapeutic range.

Apply evidence-based guidelines for supratherapeutic INR reversal.

For an INR between 4.5 and 10 without bleeding, guidelines recommend holding 1-2 doses of warfarin rather than administering pharmacological reversal agents.

Routine use of Vitamin K in this range provides no outcome benefit and can cause warfarin resistance, while PCC is exclusively for life-threatening hemorrhage.

Key Concept

Management of supratherapeutic INR without bleeding

Question 8Question →

Emergency medical services bring a 72-year-old male resident of a skilled nursing facility to the acute care setting following a two-day history of worsening confusion, fever, and purulent sputum production. Upon triage, he appears lethargic and is in mild respiratory distress. Vital signs reveal a temperature of 38.9°C (102.0°F), a blood pressure of 88/56 mmHg, a heart rate of 112/min, and a respiratory rate of 26/min. Room air pulse oximetry indicates an oxygen saturation of 89%. Auscultation of the lungs demonstrates dense, coarse crackles localized to the right lower lung base. A portable chest radiograph confirms a new dense consolidation in the right lower lobe. A review of his electronic medical record reveals a prior ischemic stroke complicated by oropharyngeal dysphagia. Notably, he was discharged from the hospital one month ago after being treated for complicated pyelonephritis with a 10-day course of intravenous levofloxacin. Blood and sputum cultures are sent to the laboratory.

Which of the following antimicrobial agents should be included in his initial empiric pharmacologic regimen? (Select all that apply)

Select all that apply

Vancomycin

Cefepime

Ceftriaxone

Levofloxacin

Metronidazole

Show answer & explanation

Answer: Vancomycin; Cefepime

Answer

Vancomycin and cefepime

The correct combination includes vancomycin and cefepime. This patient presents with severe pneumonia and has specific risk factors for resistant pathogens, namely a recent hospitalization and receipt of intravenous antibiotics within the past 90 days. Therefore, empiric therapy must be broadened beyond standard community-acquired regimens to cover Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Vancomycin provides the necessary MRSA coverage, while cefepime serves as an appropriate anti-pseudomonal beta-lactam.

Step-by-Step Solution

Assess the severity of the pneumonia and identify risk factors for resistant organisms.

The patient has severe pneumonia with risk factors for MRSA and Pseudomonas aeruginosa due to a recent hospitalization and receipt of intravenous antibiotics in the last 90 days.

Identifying risk factors for resistant pathogens dictates the need to broaden empiric antimicrobial coverage beyond standard community-acquired pneumonia regimens.

Select appropriate empiric antimicrobial agents based on the identified risk factors.

Select an anti-MRSA agent (vancomycin) and an anti-pseudomonal beta-lactam (cefepime).

Standard community-acquired regimens are insufficient for this patient; dual coverage targeting both MRSA and Pseudomonas is required to optimize survival.

Key Concept

Patients presenting with severe pneumonia who have specific risk factors (e.g., recent hospitalization and intravenous antibiotic use within the past 90 days) require empiric broad-spectrum coverage targeting both MRSA and Pseudomonas aeruginosa.

Question 9Question →

An internist is preparing hospital discharge orders for a $69$ -year-old male who was admitted four days ago for an acute exacerbation of heart failure. The patient has a known history of ischemic cardiomyopathy with a left ventricular ejection fraction of $25\%$ , type 2 diabetes mellitus, and stage 3 chronic kidney disease. Following successful intravenous diuresis, he is now euvolemic and breathing comfortably on room air.

Vital signs today show a blood pressure of $118/74$ mmHg and a heart rate of $72$ /min.

Current medications planned for discharge include:
- Lisinopril $20$ mg daily
- Carvedilol $12.5$ mg twice daily
- Dapagliflozin $10$ mg daily
- Oral torsemide $20$ mg daily

Laboratory results obtained this morning:

Test	Result
Sodium	$139$ mEq/L
Potassium	$4.3$ mEq/L
Blood urea nitrogen	$24$ mg/dL
Creatinine	$1.6$ mg/dL (baseline $1.5$ mg/dL)

To fully optimize guideline-directed medical therapy, the internist plans to prescribe spironolactone before the patient leaves the hospital.

Which of the following is the most appropriate action or instruction regarding the addition of this medication?

Initiate the medication and arrange for a follow-up basic metabolic panel in one to two weeks.

Advise the patient to replace dietary sodium with a potassium-enriched salt substitute.

Discontinue lisinopril to prevent the synergistic development of life-threatening hyperkalemia.

Defer initiation of the medication because the current serum creatinine level is an absolute contraindication.

Prescribe the medication and concurrently start daily naproxen to reduce the risk of diuretic-induced gout flares.

Show answer & explanation

Answer: Initiate the medication and arrange for a follow-up basic metabolic panel in one to two weeks.

Answer

The most appropriate action is to initiate the medication and arrange for a follow-up basic metabolic panel in one to two weeks.

The correct answer involves initiating the medication and scheduling a follow-up metabolic panel in one to two weeks. Mineralocorticoid receptor antagonists (MRAs) such as spironolactone provide a significant mortality benefit in patients with heart failure with reduced ejection fraction (HFrEF). However, because they are potassium-sparing diuretics, their use carries a substantial risk of hyperkalemia and worsening renal function. This risk is heavily amplified in patients with underlying chronic kidney disease and those concurrently taking ACE inhibitors (like lisinopril), ARBs, or ARNIs. Therefore, clinical guidelines strongly recommend checking serum potassium and renal function within

1

2

weeks after initiating an MRA or increasing its dose to prevent life-threatening hyperkalemia.

Step-by-Step Solution

Identify the patient's underlying conditions and current status.

The patient has heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease, and is currently euvolemic on a regimen of lisinopril, carvedilol, dapagliflozin, and torsemide.

Establishing the clinical baseline is necessary to determine what guideline-directed therapies are missing and what risks they may pose.

Evaluate the safety and indications for adding spironolactone.

Spironolactone is a mineralocorticoid receptor antagonist (MRA) indicated for HFrEF to reduce mortality. The patient's creatinine (

1.6

mg/dL) and potassium (

4.3

mEq/L) are within safe parameters for initiation.

MRAs are contraindicated in severe renal failure or baseline hyperkalemia, so lab values must be verified before prescribing.

Determine the necessary follow-up protocol for the new medication.

Guidelines mandate checking a basic metabolic panel within

1

2

weeks of starting an MRA.

The combination of an MRA, an ACE inhibitor (lisinopril), and baseline chronic kidney disease significantly elevates the risk of acute hyperkalemia and renal dysfunction, requiring prompt surveillance.

Key Concept

Initiation of mineralocorticoid receptor antagonists in heart failure requires close laboratory monitoring of potassium and renal function, typically within 1 to 2 weeks, due to the risk of hyperkalemia, especially when co-administered with ACE inhibitors.

Question 10Question →

A 52-year-old man comes to the clinic for an urgent evaluation due to new-onset hand tremors and worsening headaches over the past three days. He underwent a deceased-donor renal transplantation eight months ago for end-stage renal disease secondary to polycystic kidney disease. His maintenance immunosuppression regimen consists of tacrolimus, mycophenolate mofetil, and low-dose prednisone. Two weeks ago, he was seen at a local urgent care clinic for a sore throat and thick, white, scrapable plaques on his tongue and buccal mucosa. He was prescribed a 14-day course of an oral medication for this condition. Today, his temperature is 37.1°C (98.8°F), blood pressure is 158/92 mm Hg, and pulse is 88/min. Physical examination is notable for a fine resting tremor in both hands. Laboratory studies reveal a serum creatinine of 2.4 mg/dL, which is significantly elevated from his baseline of 1.3 mg/dL measured one month ago. Which of the following medications was most likely prescribed at the urgent care clinic?

Acyclovir

Clindamycin

Fluconazole

Nystatin

Terbinafine

Show answer & explanation

Answer: Fluconazole

Answer

Fluconazole

The correct answer is the oral triazole antifungal, fluconazole. The patient's initial presentation of thick, white, scrapable plaques on the oral mucosa is diagnostic of oropharyngeal candidiasis (oral thrush), a common opportunistic infection in solid organ transplant recipients on maintenance immunosuppression. His current symptoms of acute kidney injury (elevated creatinine), new-onset tremors, headache, and hypertension are hallmark features of calcineurin inhibitor (tacrolimus) toxicity. Tacrolimus is primarily metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme system. Fluconazole is a potent inhibitor of CYP3A4. When fluconazole is coadministered with tacrolimus, it significantly impairs tacrolimus clearance, leading to elevated systemic trough levels and subsequent nephrotoxicity and neurotoxicity. In clinical practice, if systemic azole therapy is required in a patient on a calcineurin inhibitor, empirical preemptive dose reduction of the calcineurin inhibitor and close therapeutic drug monitoring are mandatory.

Step-by-Step Solution

Diagnose the antecedent condition described as thick, white, scrapable plaques on the oral mucosa.

The clinical description is highly specific for oropharyngeal candidiasis (oral thrush), an opportunistic fungal infection common in immunosuppressed patients.

Identifying the initial infection is necessary to determine which class of medication was prescribed at the urgent care clinic.

Identify the cause of the patient's current symptoms (tremors, headache, hypertension, and acute kidney injury).

The presentation is classic for calcineurin inhibitor (tacrolimus) toxicity.

Tacrolimus has a narrow therapeutic index; elevated serum levels cause prominent nephrotoxicity and neurotoxicity.

Determine which treatment for oral candidiasis precipitates tacrolimus toxicity.

Fluconazole.

Tacrolimus is extensively metabolized by the hepatic and intestinal cytochrome P450 3A4 (CYP3A4) system. Systemic azole antifungals, such as fluconazole, are potent inhibitors of CYP3A4, leading to decreased tacrolimus clearance and subsequent toxicity.

Key Concept

Pharmacokinetic interactions of CYP3A4 inhibitors with calcineurin inhibitors

Estimated Time:1m 15s

Question 11Question →

Paramedics bring a 58-year-old woman to the emergency department after her husband witnessed her suddenly collapse and begin shaking. Upon arrival in the resuscitation bay, she is actively experiencing a generalized tonic-clonic seizure. Her husband states the seizure activity has been continuous for approximately 15 minutes without any return to consciousness. She has no known past medical history and takes no daily medications. Vital signs show a blood pressure of 145/90 mmHg, heart rate of 118/min, and oxygen saturation of 94% on a non-rebreather mask. Intravenous access is rapidly established by the nursing staff, and a point-of-care blood glucose level is 102 mg/dL.

Arrange the following pharmacologic interventions in the correct sequential order for the management of this patient's condition, starting from the most immediate initial therapy to the final step for super-refractory disease.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence is: 1) Administer intravenous lorazepam, 2) Administer intravenous fosphenytoin, 3) Initiate a continuous intravenous propofol infusion, 4) Initiate a continuous intravenous pentobarbital infusion.

The management of status epilepticus follows a strict time-based protocol. The initial therapy phase (0-20 minutes) requires a rapid-acting benzodiazepine such as intravenous lorazepam. This is followed by the second therapy phase (20-40 minutes), which utilizes a non-benzodiazepine antiseizure medication such as fosphenytoin to achieve sustained control. If clinical or electrographic seizures continue, the patient enters refractory status epilepticus (40-60 minutes), necessitating intubation and continuous intravenous anesthetic infusions such as propofol. Finally, if seizures persist despite general anesthesia for 24 hours or more, it is termed super-refractory status epilepticus, and profound barbiturate coma with pentobarbital or thiopental is indicated as a last resort.

Step-by-Step Solution

Identify the clinical emergency and the current duration of the event.

The patient is in generalized convulsive status epilepticus (continuous seizure >5 minutes, currently at 15 minutes).

Accurate diagnosis and timing dictate the specific phase of the treatment algorithm.

Select the first-line pharmacologic intervention.

Intravenous lorazepam is administered immediately.

Benzodiazepines are the most rapid and effective agents for acutely halting seizure activity in the initial phase (5-20 minutes).

Select the second-line pharmacologic intervention.

Intravenous fosphenytoin (or levetiracetam/valproic acid) is administered.

A long-acting non-benzodiazepine antiseizure medication must be given to prevent recurrence or to treat seizures that do not respond to the initial benzodiazepine (20-40 minute phase).

Determine the approach for refractory and super-refractory cases.

Propofol is used for refractory cases, followed by pentobarbital if super-refractory.

Anesthetic infusions like propofol or midazolam are used when standard agents fail. Pentobarbital induces a deep barbiturate coma and is strictly a last resort due to its severe hemodynamic side effects.

Key Concept

The stepwise, time-dependent pharmacologic management algorithm for generalized convulsive status epilepticus.

Question 12Question →

A 78-year-old female patient is evaluated during a routine ambulatory appointment at a geriatrics clinic. Her daughter, who provides collateral history, expresses concern regarding the patient's escalating confusion and recent onset of urinary dribbling over the past month. The patient's medical history includes major depressive disorder, essential hypertension, type 2 diabetes mellitus, and painful diabetic peripheral neuropathy. Her daily medication regimen consists of metformin, amlodipine, sertraline, amitriptyline (initiated four weeks ago for neuropathy), and over-the-counter diphenhydramine (taken nightly for insomnia).

Vital signs show a heart rate of 92/min. Blood pressure is 138/82 mm Hg while supine and 112/68 mm Hg upon standing. Physical examination is notable for dry oral mucous membranes, delayed capillary refill, and a mildly distended, palpable mass in the suprapubic region. A bedside ultrasound of the bladder demonstrates a postvoid residual volume of 550 mL.

Which of the following is the most appropriate initial pharmacologic intervention?

Initiate oral oxybutynin therapy

Initiate oral donepezil therapy

Discontinue amlodipine

Discontinue amitriptyline and diphenhydramine

Discontinue sertraline

Show answer & explanation

Answer: Discontinue amitriptyline and diphenhydramine

Answer

Discontinue amitriptyline and diphenhydramine

The correct answer involves discontinuing both amitriptyline and diphenhydramine. This patient is exhibiting a classic anticholinergic toxidrome (manifesting as confusion, dry mucous membranes, and urinary retention leading to overflow incontinence) caused by the synergistic effects of a tricyclic antidepressant (amitriptyline) and a first-generation antihistamine (diphenhydramine). Elderly patients are particularly susceptible to the cumulative anticholinergic burden of multiple medications due to decreased hepatic and renal clearance, as well as age-related changes in the central nervous system. Additionally, her significant orthostatic hypotension is a direct result of the alpha-1 adrenergic receptor blockade characteristic of tricyclic antidepressants. The most appropriate initial intervention is deprescribing these offending agents to reverse the toxicity.

Step-by-Step Solution

Analyze the patient's clinical presentation.

The patient presents with confusion, overflow urinary incontinence (postvoid residual 550 mL), dry mucous membranes, and severe orthostatic hypotension.

Synthesizing the physical findings and history is necessary to identify the underlying toxidrome.

Correlate the symptoms with the patient's medication list.

Amitriptyline and diphenhydramine are identified as medications with strong anticholinergic properties; amitriptyline additionally exerts significant alpha-1 adrenergic blocking effects.

Identifying the offending agents causing the adverse drug events is critical in the elderly, who are highly susceptible to polypharmacy cascades.

Determine the most appropriate clinical action.

The best intervention is to immediately discontinue the anticholinergic medications.

Reversing the toxidrome by removing the offending agents is the primary treatment before considering any alternative diagnostic or therapeutic pathways.

Key Concept

Cumulative anticholinergic burden in the elderly can present with delirium, overflow urinary incontinence, and dry mucous membranes, necessitating the prompt discontinuation of offending agents.

Alternative Method

A formal medication reconciliation utilizing the Beers Criteria or calculating the patient's Anticholinergic Cognitive Burden (ACB) score can systematically highlight the urgent need to deprescribe high-risk medications like amitriptyline and diphenhydramine.

Estimated Time:1m 15s

Question 13Question →

A 58-year-old man is brought to the emergency department by his wife due to fever, severe headache, and confusion that started 12 hours ago. He has a past medical history of alcohol use disorder, type 2 diabetes mellitus, and hypertension. His temperature is 39.2°C (102.6°F), blood pressure is 110/70 mmHg, and heart rate is 115/min. On physical examination, he is lethargic but arousable. There is significant resistance to passive neck flexion. Funduscopic examination shows no papilledema. Lumbar puncture is performed, and cerebrospinal fluid (CSF) analysis reveals a leukocyte count of 2,400/mm³ (90% neutrophils), a glucose level of 30 mg/dL, and a protein level of 150 mg/dL. Gram stain of the CSF is pending.

Which of the following pharmacologic agents should be included in his immediate empiric regimen? (Select all that apply)

Select all that apply

Ampicillin

Ceftriaxone

Vancomycin

Acyclovir

Gentamicin

Show answer & explanation

Answer: Ampicillin; Ceftriaxone; Vancomycin

Answer

The immediate empiric regimen should include ampicillin, ceftriaxone, and vancomycin.

The patient's clinical presentation and cerebrospinal fluid analysis are consistent with acute bacterial meningitis. In adults aged 2 to 50 years, the most common pathogens are Streptococcus pneumoniae and Neisseria meningitidis, and standard empiric therapy includes vancomycin and a third-generation cephalosporin (e.g., ceftriaxone). However, in patients older than 50 years, or those with altered cellular immunity (such as from alcohol use disorder or diabetes), there is an increased risk of infection with Listeria monocytogenes. Therefore, ampicillin must be added to the empiric regimen. The correct multi-drug regimen includes vancomycin, ceftriaxone, and ampicillin.

Step-by-Step Solution

Analyze the patient's clinical presentation and cerebrospinal fluid (CSF) findings.

The combination of fever, headache, nuchal rigidity, altered mental status, and a CSF profile with high neutrophils, low glucose, and high protein indicates acute bacterial meningitis.

Establishing the correct diagnosis dictates the choice of empiric antimicrobial therapy.

Identify the patient's demographic and medical risk factors.

The patient is over 50 years old (58 years) and has a history of alcohol use disorder and diabetes mellitus.

Age and comorbidities determine the likely causative organisms and the need for expanded antibiotic coverage.

Select the appropriate empiric antibiotic regimen based on the identified risk factors.

Vancomycin and ceftriaxone are selected for baseline coverage, while ampicillin is added specifically to cover Listeria monocytogenes.

Standard empiric therapy for adults includes vancomycin and a third-generation cephalosporin. Ampicillin must be added for patients >50 years or those who are immunocompromised.

Key Concept

Empiric antibiotic therapy for bacterial meningitis in adults >50 years or with immunocompromising conditions (such as alcoholism) requires a combination of vancomycin, a third-generation cephalosporin (e.g., ceftriaxone), and ampicillin.

Question 14Question →

A 68-year-old man is evaluated in the urgent care clinic for a 24-hour history of severe, progressive pain and swelling in his right knee. He is unable to bear weight on the affected leg. His medical history is significant for type 2 diabetes mellitus, hypertension, and stage 4 chronic kidney disease with a baseline estimated glomerular filtration rate (eGFR) of $24 \text{ mL/min/1.73 m}^2$ . Current medications include amlodipine, insulin detemir, and calcium acetate. Vital signs are temperature $37.2^\circ\text{C}$ ( $99.0^\circ\text{F}$ ), pulse 88/min, and blood pressure 138/84 mm Hg. Physical examination reveals a swollen, erythematous, and exquisitely tender right knee with a moderate effusion. Arthrocentesis is performed. Synovial fluid analysis reveals a leukocyte count of $28,000/\mu\text{L}$ (85% neutrophils) and the presence of negatively birefringent, needle-shaped crystals under polarized light microscopy. Gram stain is negative. Which of the following is the most appropriate pharmacologic intervention for this patient's acute joint condition?

Intra-articular triamcinolone

Intravenous ceftriaxone and vancomycin

Oral allopurinol

Oral colchicine

Oral indomethacin

Show answer & explanation

Answer: Intra-articular triamcinolone

Answer

Intra-articular triamcinolone is the most appropriate treatment.

Intra-articular triamcinolone is the most appropriate intervention because this patient has an acute monoarticular gout flare combined with severe chronic kidney disease (CKD stage 4). While NSAIDs, colchicine, and systemic/intra-articular glucocorticoids are all first-line options for acute gout in healthy individuals, patient comorbidities dictate the final choice. In severe renal impairment (eGFR <30 mL/min/1.73 m^2), NSAIDs are absolutely contraindicated due to the risk of precipitating acute-on-chronic renal failure. Colchicine should also be avoided due to the high risk of fatal toxicity. For a single accessible inflamed joint, intra-articular glucocorticoids provide rapid, targeted relief with minimal systemic absorption.

Step-by-Step Solution

Interpret the synovial fluid analysis results.

The presence of negatively birefringent, needle-shaped crystals confirms the diagnosis of acute gouty arthritis. The elevated leukocyte count of 28,000/μL is an expected inflammatory response to the crystals.

Establishing a definitive crystal diagnosis eliminates the immediate need for empiric antibiotics despite the highly inflammatory fluid.

Review the patient's medical history for contraindications to standard therapies.

The patient has stage 4 chronic kidney disease (eGFR 24 mL/min/1.73 m^2).

Comorbidities dictate the safety profile of acute gout therapies. Standard first-line agents (NSAIDs and colchicine) rely on renal clearance or can directly damage the kidneys.

Select the optimal pharmacologic intervention based on the clinical presentation and safety profile.

Intra-articular triamcinolone is selected.

Because the patient has a monoarticular flare (one accessible joint) and severe renal impairment, a local glucocorticoid injection provides excellent efficacy while avoiding the systemic nephrotoxicity of NSAIDs and the systemic neuromyopathy risk of colchicine.

Key Concept

In patients with acute monoarticular gout and severe chronic kidney disease (eGFR < 30 mL/min/1.73 m^2), NSAIDs and colchicine are contraindicated; intra-articular glucocorticoids are the preferred first-line therapy.

Question 15Question →

A 58-year-old man is evaluated in the hospital for a 5-day history of fever, nonproductive cough, and right-sided pleuritic chest pain. He underwent a deceased-donor renal transplantation eight months ago and is maintained on a daily immunosuppressive regimen of tacrolimus, mycophenolate mofetil, and low-dose prednisone. Vital signs are temperature $38.6^\circ\text{C}$ ( $101.5^\circ\text{F}$ ), pulse $108/\text{min}$ , respirations $20/\text{min}$ , and blood pressure $138/82\text{ mm Hg}$ . Chest computed tomography reveals a dense right upper lobe nodule with a surrounding halo of ground-glass attenuation. Serum galactomannan assay is strongly positive, and bronchoscopy with bronchoalveolar lavage confirms the diagnosis of invasive pulmonary aspergillosis. The medical team decides to initiate the standard first-line targeted intravenous antifungal therapy for this condition. Which of the following concurrent pharmacologic interventions is most appropriate for this patient?

Decrease the current dosage of tacrolimus

Increase the current dosage of tacrolimus

Initiate high-dose intravenous methylprednisolone

Initiate intravenous fluconazole therapy

Withhold antifungal therapy pending fungal blood culture results

Show answer & explanation

Answer: Decrease the current dosage of tacrolimus

Answer

Decrease the current dosage of tacrolimus

This patient has a confirmed diagnosis of invasive pulmonary aspergillosis (IPA), indicated by the halo sign on CT and positive galactomannan. The standard-of-care targeted pharmacologic intervention is voriconazole. Voriconazole is a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme. Tacrolimus, a calcineurin inhibitor crucial for preventing renal allograft rejection, has a narrow therapeutic index and is heavily metabolized by CYP3A4 in the liver and intestines. Concurrent initiation of voriconazole will dramatically reduce tacrolimus clearance, leading to toxic serum trough levels. This toxicity typically manifests as severe acute kidney injury (which is especially dangerous in a renal transplant recipient), hypertension, and neurologic complications such as seizures or posterior reversible encephalopathy syndrome (PRES). To safely manage this patient, the clinician must preemptively decrease the dosage of tacrolimus (often by 30% to 50%) when starting voriconazole and rigorously monitor serum trough levels.

Step-by-Step Solution

Identify the primary diagnosis and the standard-of-care medication required.

The patient has invasive pulmonary aspergillosis (IPA). The first-line targeted pharmacologic therapy is intravenous voriconazole.

Establishing the specific antimicrobial required is necessary to evaluate its impact on the patient's complex baseline medication regimen.

Analyze the pharmacokinetic profile of the intended treatment against the patient's active medication list.

Voriconazole is a strong inhibitor of the hepatic cytochrome P450 3A4 (CYP3A4) enzyme system. The patient is taking tacrolimus, which is extensively metabolized by CYP3A4.

Identifying drug-drug interactions is critical in transplant patients to prevent organ rejection or drug toxicity.

Determine the necessary dosage adjustment based on the interaction.

Because voriconazole will inhibit the clearance of tacrolimus, the serum concentration of tacrolimus will rise significantly. The tacrolimus dose must be preemptively decreased (often by 1/3 to 1/2) and blood trough levels monitored closely.

Failure to reduce the dose will lead to acute calcineurin-inhibitor toxicity, manifesting as acute kidney injury, tremor, or seizures.

Key Concept

Initiation of voriconazole (a strong CYP3A4 inhibitor) for invasive aspergillosis requires a preemptive dose reduction of calcineurin inhibitors (like tacrolimus or cyclosporine) to prevent life-threatening drug toxicity.

Estimated Time:1m 30s

Question 16Question →

Evaluation is underway for a patient hospitalized on the medical ward who is recovering from an exacerbation of chronic obstructive pulmonary disease. The patient, who has a past medical history of heart failure with preserved ejection fraction, paroxysmal atrial fibrillation, and major depressive disorder, was initially treated with intravenous methylprednisolone and continuous nebulized albuterol. His symptoms have significantly improved, and he is now breathing comfortably on room air.

His home medications, which were continued during the admission, include diltiazem, apixaban, escitalopram, and atorvastatin. Morning laboratory results are notable for a serum potassium level of $3.1 \text{ mEq/L}$ and a serum magnesium level of $1.6 \text{ mg/dL}$ . A routine 12-lead electrocardiogram performed today shows normal sinus rhythm with a QTc interval of $530 \text{ milliseconds}$ . Before the planned discharge, a sputum polymerase chain reaction panel returns positive for Mycoplasma pneumoniae, prompting the decision to initiate targeted oral antibiotic therapy.

Which of the following is the most appropriate antimicrobial regimen to prescribe for this patient?

Oral doxycycline

Oral azithromycin

Oral clarithromycin

Oral amoxicillin-clavulanate

Oral levofloxacin

Show answer & explanation

Answer: Oral doxycycline

Answer

The correct answer is oral doxycycline.

The correct answer is oral doxycycline. This patient requires targeted antibiotic therapy for an atypical pneumonia caused by Mycoplasma pneumoniae. The standard treatment options for atypical respiratory pathogens include macrolides, fluoroquinolones, and tetracyclines. However, this patient has multiple major risk factors for drug-induced Torsades de Pointes: a critically prolonged baseline QTc interval of

530 \text{ milliseconds}

, uncorrected hypokalemia and hypomagnesemia, and concurrent therapy with escitalopram, which is also known to prolong the QT interval. Doxycycline provides excellent antimicrobial coverage for Mycoplasma species and does not prolong the QT interval. Furthermore, doxycycline does not exhibit dangerous pharmacokinetic interactions with the patient's other high-risk medications, such as apixaban and diltiazem, making it the safest and most effective pharmacologic choice.

Step-by-Step Solution

Identify the primary diagnosis and the targeted organism.

The patient has a confirmed Mycoplasma pneumoniae infection superimposed on a chronic obstructive pulmonary disease exacerbation.

The positive sputum polymerase chain reaction indicates an atypical bacterial infection requiring specific antimicrobial coverage.

Determine the standard treatment options for the identified pathogen.

Mycoplasma pneumoniae is typically treated with macrolides (e.g., azithromycin, clarithromycin), fluoroquinolones (e.g., levofloxacin, moxifloxacin), or tetracyclines (e.g., doxycycline).

These classes of antibiotics are active against cell-wall deficient atypical organisms.

Analyze the patient's baseline risk factors and current medication list.

The patient has a severely prolonged QTc interval (

530 \text{ ms}

), uncorrected hypokalemia (

3.1 \text{ mEq/L}

), hypomagnesemia (

1.6 \text{ mg/dL}

), and is taking escitalopram.

Identifying contraindications is crucial before prescribing new medications to avoid life-threatening adverse drug events.

Evaluate the safety profile of the potential antibiotics.

Macrolides and fluoroquinolones are absolutely contraindicated due to their potential to further prolong the QT interval and trigger Torsades de Pointes.

Doxycycline is the only appropriate agent from the list that does not carry the risk of QT prolongation.

Key Concept

Doxycycline is the preferred antibiotic for treating atypical pneumonia in patients with a prolonged QTc interval or taking QT-prolonging medications, as it lacks the arrhythmogenic risks associated with macrolides and fluoroquinolones.

Question 17Question →

A 62-year-old man is brought to the emergency department by emergency medical services (EMS) due to the sudden onset of difficulty breathing, facial swelling, and a diffuse pruritic rash. The symptoms began 15 minutes ago while he was eating at a seafood restaurant. His medical history is significant for hypertension, coronary artery disease, and heart failure with preserved ejection fraction. His home medications include lisinopril, metoprolol, aspirin, and atorvastatin. Upon arrival, his blood pressure is 74/40 mm Hg, pulse is 62/min, and oxygen saturation is 90% on room air. Physical examination reveals marked angioedema of the lips, widespread urticaria, and diffuse bilateral expiratory wheezing. EMS has established peripheral intravenous access.

Arrange the following pharmacologic interventions in the correct sequential order of administration for the acute escalation of therapy in this patient.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence is: 1) Administer intramuscular epinephrine, 2) Administer a rapid intravenous bolus of 0.9% sodium chloride, 3) Administer intravenous glucagon, 4) Initiate a continuous intravenous epinephrine infusion.

The correct sequential management for severe anaphylactic shock in a patient taking beta-blockers follows a distinct escalation pathway. First, intramuscular epinephrine is the absolute first-line therapy and must never be delayed. Second, for persistent hypotension, aggressive intravenous fluid resuscitation with isotonic crystalloids (0.9% sodium chloride) is the next immediate step to counteract massive vasodilation and capillary leak. Third, because this patient is on metoprolol, his beta-adrenergic receptors are blocked, which can render standard epinephrine less effective (evidenced by his lack of compensatory tachycardia). In such refractory cases, intravenous glucagon is administered because it increases intracellular cAMP and provides inotropic and chronotropic effects independent of beta-receptors. Finally, if the patient remains in shock despite these interventions, a continuous intravenous epinephrine infusion is initiated to maintain perfusion.

Step-by-Step Solution

Diagnose the acute condition based on the clinical presentation.

The patient is experiencing severe anaphylactic shock.

Sudden onset of dyspnea, angioedema, urticaria, wheezing, and profound hypotension after allergen exposure (seafood) confirm anaphylaxis.

Identify the critical home medication influencing the presentation.

The patient is taking metoprolol, a beta-blocker.

The relative bradycardia (pulse 62/min) in the setting of severe distributive shock suggests beta-blockade, which blunts the compensatory tachycardic response and can render standard epinephrine doses ineffective.

Select the immediate first-line pharmacologic intervention.

Administer intramuscular epinephrine.

Intramuscular epinephrine is the life-saving first step for all anaphylaxis patients to halt mast cell degranulation, regardless of concurrent beta-blocker use.

Determine the next step for persistent distributive shock.

Administer a rapid intravenous bolus of 0.9% sodium chloride.

Aggressive fluid resuscitation is required to counteract the massive capillary leak and vasodilation that occurs in anaphylaxis.

Select the specific antidote for beta-blocker-associated refractory anaphylaxis.

Administer intravenous glucagon.

Glucagon bypasses the blocked beta-adrenergic receptors to increase intracellular cAMP, providing essential inotropic and chronotropic support as well as bronchodilation.

Identify the final escalation step if the patient remains in shock.

Initiate a continuous intravenous epinephrine infusion.

When intermittent intramuscular doses, fluids, and glucagon fail to restore perfusion, a continuous vasopressor infusion is necessary.

Key Concept

The correct escalation sequence for managing refractory anaphylaxis in a patient on beta-blockers is intramuscular epinephrine, followed by intravenous fluid resuscitation, intravenous glucagon, and finally continuous intravenous epinephrine infusion.

Estimated Time:1m 30s

Question 18Question →

A 62-year-old woman is evaluated in the emergency department for right lower extremity swelling and pain that began 2 days ago. Her past medical history is significant for hypertension, type 2 diabetes mellitus, and end-stage renal disease requiring hemodialysis three times a week. Vital signs include a temperature of 37.1°C (98.8°F), blood pressure of 142/86 mmHg, pulse of 88/min, and respiratory rate of 14/min. Physical examination reveals a swollen, tender, and erythematous right calf. A comprehensive metabolic panel is notable for a blood urea nitrogen of 42 mg/dL and a serum creatinine of 5.8 mg/dL. Compression ultrasonography of the right lower extremity demonstrates a noncompressible right popliteal vein. Which of the following is the most appropriate initial pharmacologic intervention for this patient?

Intravenous unfractionated heparin

Subcutaneous enoxaparin

Subcutaneous fondaparinux

Oral dabigatran

Oral warfarin

Show answer & explanation

Answer: Intravenous unfractionated heparin

Answer

Intravenous unfractionated heparin

The correct intervention is intravenous unfractionated heparin. This patient has an acute deep vein thrombosis (DVT) and requires immediate systemic anticoagulation. Because she has end-stage renal disease (ESRD) on hemodialysis, medications that are primarily cleared by the kidneys are contraindicated due to the risk of drug accumulation and severe bleeding. Unfractionated heparin undergoes hepatic metabolism and reticuloendothelial clearance, making it the preferred and safest initial parenteral anticoagulant for patients with a creatinine clearance of less than 30 mL/min.

Step-by-Step Solution

Diagnose the acute condition based on clinical presentation and ultrasound findings.

The patient has an acute right popliteal deep vein thrombosis (DVT).

Swelling, pain, erythema, and a noncompressible vein on compression ultrasonography are diagnostic of an acute DVT.

Identify significant comorbidities that affect pharmacologic management.

The patient has end-stage renal disease (ESRD) on hemodialysis.

Renal failure alters the clearance of many common anticoagulants, necessitating alternative selections.

Select the appropriate anticoagulant that is safe for immediate use in ESRD.

Intravenous unfractionated heparin is selected.

Unlike low-molecular-weight heparins or certain direct oral anticoagulants, unfractionated heparin is hepatically cleared and safe to use in patients with severe renal impairment.

Key Concept

Selection of safe initial anticoagulation in patients with end-stage renal disease

Question 19Question →

A 56-year-old man is brought to the emergency department by ambulance after vomiting a large amount of bright red blood. He has a history of alcohol use disorder and compensated cirrhosis. On arrival, he is lethargic but localizes to pain and maintains his airway. Blood pressure is 88/55 mm Hg, and pulse is 118/min. Physical examination reveals scleral icterus, palmar erythema, and a distended abdomen with shifting dullness. Two large-bore peripheral intravenous lines are placed, and fluid resuscitation with isotonic crystalloid is initiated. Laboratory studies show:

Laboratory Parameter	Result
Hemoglobin	8.2 g/dL
Platelet count	75,000/mm³
Prothrombin time	18 seconds
INR	1.8

Which of the following pharmacologic interventions are most appropriate for this patient at this time? (Select all that apply)

Select all that apply

Intravenous octreotide

Intravenous ceftriaxone

Intravenous propranolol

Intravenous fresh frozen plasma

Enteral lactulose

Show answer & explanation

Answer: Intravenous octreotide; Intravenous ceftriaxone

Answer

The most appropriate interventions are intravenous octreotide and intravenous ceftriaxone.

In the setting of suspected acute variceal hemorrhage, initial pharmacologic therapy focuses on reducing portal venous pressure and preventing severe infectious complications. Intravenous octreotide, a somatostatin analog, inhibits the release of vasodilator hormones (such as glucagon), leading to splanchnic vasoconstriction and a subsequent decrease in portal inflow and variceal pressure. Concurrently, bacterial infections (particularly spontaneous bacterial peritonitis) are a major trigger and complication of variceal bleeding in cirrhosis. The administration of prophylactic antibiotics, typically intravenous ceftriaxone, has been definitively shown to reduce both rebleeding rates and overall mortality, making it a mandatory initial intervention.

Step-by-Step Solution

Analyze the patient's clinical presentation and vital signs.

The patient has signs of hemorrhagic shock (hypotension, tachycardia) secondary to acute upper gastrointestinal bleeding, highly suspicious for variceal hemorrhage given his history of cirrhosis and stigmata of chronic liver disease.

Establishing the severity and likely etiology of the bleeding dictates the immediate resuscitative and pharmacologic priorities.

Evaluate the indication for portal pressure reduction and infection prophylaxis.

Octreotide must be initiated to reduce splanchnic blood flow. Ceftriaxone must be initiated because cirrhotic patients with GI bleeding are at high risk for spontaneous bacterial peritonitis and bacteremia.

These two interventions are the cornerstone of initial medical management for suspected variceal bleeding and have been shown to reduce mortality.

Assess standard treatments that might be contraindicated in this specific acute setting.

Propranolol, fresh frozen plasma (FFP), and enteral lactulose are rejected.

Propranolol causes shock in acute bleeding; FFP increases portal pressure without correcting the complex cirrhotic coagulopathy; and enteral lactulose poses an aspiration risk during active hematemesis.

Key Concept

The initial pharmacologic management of acute variceal bleeding in cirrhosis requires splanchnic vasoconstrictors (e.g., octreotide) to decrease portal pressure and prophylactic antibiotics (e.g., ceftriaxone) to prevent mortality-increasing infections.

Question 20Question →

A 68-year-old male with a history of type 2 diabetes mellitus is admitted to the intensive care unit due to severe community-acquired pneumonia and worsening hypotension. His weight is 80 kg. Upon arrival, his blood pressure is 75/40 mm Hg, heart rate is 128/min, and respiratory rate is 28/min. Initial laboratory results demonstrate a serum lactate of 5.2 mmol/L. Appropriate empiric broad-spectrum antibiotics have already been administered. Arrange the following pharmacologic interventions in the correct sequential order of escalation for managing this patient's hemodynamics, assuming he remains persistently hypotensive after each preceding step is fully implemented.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence is to first administer a 30 mL/kg fluid bolus (2.4 L balanced crystalloid), followed by starting a norepinephrine infusion if hypotension persists. If the mean arterial pressure remains inadequate, a vasopressin infusion should be added next. Finally, if the patient is in refractory shock despite fluids and vasopressors, intravenous hydrocortisone is indicated.

The Surviving Sepsis Campaign guidelines emphasize a strict stepwise approach to hemodynamic resuscitation. Initial stabilization requires rapidly restoring intravascular volume with a 30 mL/kg bolus of crystalloids. If the mean arterial pressure (MAP) remains below 65 mm Hg after fluids, the first-line vasopressor, norepinephrine, must be initiated. Vasopressin is subsequently added to augment vascular tone and reduce the required dose of norepinephrine. Intravenous corticosteroids (hydrocortisone) are reserved as a final pharmacologic step for refractory shock that does not respond to adequate fluids and multiple vasopressor therapies.

Step-by-Step Solution

Administer 30 mL/kg of intravenous crystalloids (2.4 L).

Initial restoration of intravascular volume.

Sepsis causes profound vasodilation and capillary leak; guidelines mandate an initial fluid bolus within the first 3 hours to correct absolute and relative hypovolemia.

Initiate intravenous norepinephrine.

Vasoconstriction and increase in mean arterial pressure.

If the mean arterial pressure remains below 65 mm Hg despite adequate fluid resuscitation, norepinephrine is the primary first-line vasopressor to restore vascular tone.

Add intravenous vasopressin.

Synergistic vasoconstriction and catecholamine sparing.

Vasopressin is added when norepinephrine doses are escalating or inadequate, acting via V1 receptors to increase blood pressure without further adrenergic stimulation.

Administer intravenous hydrocortisone.

Reversal of relative adrenal insufficiency.

Corticosteroids are indicated exclusively for refractory septic shock that does not respond to adequate fluid resuscitation and moderate-to-high doses of multiple vasopressors.

Key Concept

The stepwise hemodynamic escalation protocol for septic shock: Crystalloids -> Norepinephrine -> Vasopressin -> Corticosteroids.

Page 1 / 18Next

Pharmacologic Interventions

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Alternative Method

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Alternative Method

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Alternative Method

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes